; onclick=)
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/ceritinib-uses-dosage-side-effects-interaction_245498.jpg?fit=800%2C600&ssl=1" class="aligncenter wp-post-image" alt="" decoding="async" srcset="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/ceritinib-uses-dosage-side-effects-interaction_245498.jpg?w=800&ssl=1 800w, https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/ceritinib-uses-dosage-side-effects-interaction_245498.jpg?resize=768%2C576&ssl=1 768w, https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/ceritinib-uses-dosage-side-effects-interaction_245498.jpg?resize=360%2C270&ssl=1 360w, https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/ceritinib-uses-dosage-side-effects-interaction_245498.jpg?resize=600%2C450&ssl=1 600w" sizes="(max-width: 800px) 100vw, 800px" data-attachment-id="255627" data-permalink="https://rxharun.com/rxharun/drug-a-z/ceritinib/attachment/ceritinib-uses-dosage-side-effects-interaction/" data-orig-file="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/ceritinib-uses-dosage-side-effects-interaction_245498.jpg?fit=800%2C600&ssl=1" data-orig-size="800,600" data-comments-opened="0" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="Ceritinib – Uses, Dosage, Side Effects, Interaction" data-image-description="" data-image-caption="" data-medium-file="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/ceritinib-uses-dosage-side-effects-interaction_245498.jpg?fit=800%2C600&ssl=1" data-large-file="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/ceritinib-uses-dosage-side-effects-interaction_245498.jpg?fit=800%2C600&ssl=1" data-jpibfi-post-excerpt="" data-jpibfi-post-url="https://rxharun.com/rxharun/drug-a-z/ceritinib/" data-jpibfi-post-title="Ceritinib – Uses, Dosage, Side Effects, Interaction" data-jpibfi-src="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/ceritinib-uses-dosage-side-effects-interaction_245498.jpg?fit=800%2C600&ssl=1">
Ceritinib is an orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ceritinib binds to and inhibits wild-type ALK kinase, ALK fusion proteins, and ALK point mutation variants. Inhibition of ALK leads to both the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types.
Ceritinib is a small molecule tyrosine kinase receptor inhibitor and antineoplastic agent that is used in the therapy of selected forms of advanced non-small cell lung cancer (NSCLC). Ceritinib is associated with a moderate rate of serum aminotransferase elevations during therapy and rare instances of clinically apparent acute liver injury.
Ceritinib is a member of the class of amino pyrimidines that is 2,6-diamino-5-fluoropyrimidine in which the amino groups at positions 2 and 6 are respectively carrying 2-methoxy-4-(piperidin-4-yl)-5-methyl phenyl and 2-(isopropylsulfonyl)phenyl substituents. Used for the treatment of ALK-positive metastatic non-small cell lung cancer. It has a role as an antineoplastic agent and an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor. It is an aminopyrimidine, an aromatic ether, an organochlorine compound, a secondary amino compound, a member of piperidines, and a sulfone.
Mechanism of Action
Ceritinib inhibits Anaplastic lymphoma kinase (ALK) also known as ALK tyrosine kinase receptor or CD246 (cluster of differentiation 246), which is an enzyme that in humans is encoded by the ALK gene. About 4-5% of NSCLCs have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase), which results in constitutive kinase activity that contributes to carcinogenesis and seems to drive the malignant phenotype. Ceritinib exerts its therapeutic effect by inhibiting autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells. Ceritinib has been shown to inhibit in vitro proliferation of cell lines expressing EML4-ALK and NPM-ALK fusion proteins and demonstrated dose-dependent inhibition of EML4-ALK-positive NSCLC xenograft growth in mice and rats.
or
Ceritinib is a tyrosine kinase inhibitor that selectively and potently inhibits anaplastic lymphoma kinase (ALK). In normal physiology, ALK functions as a key step in the development and function of nervous system tissue. However, chromosomal translocation and fusion give rise to an oncogenic form of ALK that has been implicated in the progression of NSCLC. Ceritinib thus acts to inhibit this mutated enzyme and stop cell proliferation, ultimately halting cancer progression.[rx] Because ceritinib is considered a targeted cancer therapy, an FDA-approved test is required to determine which patients are candidates for ceritinib. This test, developed by Roche, is the VENTANA ALK (D5F3) CDx Assay and is used to identify ALK-positive NSCLC patients who would benefit from ceritinib treatment.[rx]
Indications
- Ceritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
- Ceritinib is a small molecule tyrosine kinase receptor inhibitor and antineoplastic agent that is used in the therapy of selected forms of advanced non-small cell lung cancer (NSCLC)
- Zykadia is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.
- Ceritinib is approved to treat Non-small cell lung cancer that is ALK-positive and has metastasized (spread to other parts of the body). It is used in adults.
- Refractory, locally advanced Nonsmall cell lung cancer
- Refractory, metastatic Non-small cell lung cancer
Use in Cancer
Ceritinib is approved to treat:
- Non-small cell lung cancer that is ALK-positive and has metastasized (spread to other parts of the body). It is used in adults.
Ceritinib is also being studied in the treatment of other types of cancer.
Contraindications
- low amount of magnesium in the blood
- low amount of calcium in the blood
- low amount of potassium in the blood
- slow heartbeat
- prolonged QT interval on EKG
- chronic heart failure
- abnormal EKG with QT changes from birth
- high amount of bilirubin in the blood
- excessive nausea
- excessive vomiting
- excessive diarrhea
- high blood sugar
- abnormal liver function tests
- pregnancy
- a patient who is producing milk and breastfeeding
- lung tissue problem
- pancreatitis
Dosage
Strengths: 150 mg
Non-Small Cell Lung Cancer
- 450 mg orally once daily at the same time each day until disease progression or unacceptable toxicity
- Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib
Dose Adjustments
DOSE MODIFICATIONS:
- First dose reduction: 300 mg once a day
- Second dose reduction: 150 mg once a day
- Discontinue this drug in patients unable to tolerate 150 mg daily.
DOSE MODIFICATIONS FOR ADVERSE REACTIONS:
GI ADVERSE REACTIONS:
- Severe or intolerable nausea, vomiting, or diarrhea despite antiemetic or antidiarrheal therapy: Withhold therapy until improved; resume at the next lower dose.
HEPATOTOXICITY:
- ALT or AST elevation greater than 5 times the upper limit of normal (ULN) with total bilirubin elevation less than or equal to 2 x ULN: Withhold therapy until recovery to baseline or less than or equal to 3 x ULN; resume at the next lower dose.
- ALT or AST elevation greater than 3 x ULN with total bilirubin elevation greater than 2 x ULN in the absence of cholestasis or hemolysis: Permanently discontinue therapy.
INTERSTITIAL LUNG DISEASE (ILD)/PNEUMONITIS:
- Any Grade therapy-related ILD/pneumonitis: Permanently discontinue therapy.
QT INTERVAL PROLONGATION:
- QTc interval greater than 500 msec on at least 2 separate ECGs: Withhold therapy until QTc interval is less than 481 msec or recovery to baseline if baseline QTc is greater than or equal to 481 msec; resume at the next lower dose.
- QTc interval prolongation in combination with Torsades de pointes or polymorphic ventricular tachycardia or serious arrhythmia: Permanently discontinue therapy.
HYPERGLYCEMIA:
- Persistent hyperglycemia greater than 250 mg/dL despite antihyperglycemic therapy: Withhold therapy until hyperglycemia is adequately controlled; resume at the next lower dose; if adequate hyperglycemic control cannot be achieved with medical management, discontinue this drug.
BRADYCARDIA:
- Symptomatic bradycardia that is not life-threatening: Withhold therapy until recovery to asymptomatic bradycardia or to the heart rate of 60 bpm or above, evaluate concomitant medications known to cause bradycardia; if bradycardia cannot be attributed to another drug, resume therapy at the next lower dose.
- Clinically significant bradycardia requiring intervention or life-threatening bradycardia in patients taking a concomitant medication also known to cause bradycardia or a medication known to cause hypotension: Permanently discontinue therapy.
PANCREATITIS:
- Lipase or amylase elevation greater than 2 x ULN: Withhold therapy until recovery to less than 1.5 x ULN; resume at the next lower dose.
STRONG CYP450 3A INHIBITORS (e.g. ketoconazole):
- Avoid use if possible.
- If users cannot be avoided, reduce the dose of ceritinib by approximately one-third rounded to the nearest multiple of 150 mg.
- After discontinuation of a strong CYP450 3A inhibitor, resume the ceritinib dose that was taken prior to initiating the strong CYP450 3A inhibitor.
Administration Advice:
- This drug should be taken with food.
- Do not consume grapefruit or grapefruit juice because they inhibit CYP450 3A.
- If a dose is missed, make it up unless it is 12 hours or less until the next dose.
- Discontinue in patients unable to tolerate 300 mg a day.
Side Effects
The Most Common
- nausea
- diarrhea
- vomiting
- constipation
- stomach pain
- heartburn
- difficulty swallowing
- loss of appetite
- weight loss
- fatigue
- rash
- itching
- changes in vision
- muscle, bone, back arm, or leg pain
- headache
- pain in the right upper part of the stomach
- unusual bruising or bleeding
- dark urine
- yellowing of the skin and eyes
- decreased appetite
- flu-like symptoms
- itching
- shortness of breath
- fever, chills, sore throat, ongoing cough and congestion, or other signs of infection
- chest pain or discomfort
- changes in heartbeat
- heart palpitations
- dizziness
- lightheadedness
- fainting
- ongoing pain that begins in the upper left or middle of the stomach but may spread to the back
- seizures
More Common
- severe pain in your upper stomach spreading to your back;
- slow heartbeats, weak pulse, weak or shallow breathing;
- sudden chest pain or discomfort, fever, dry cough or cough with mucus, feeling short of breath;
- fast or pounding heartbeats, fluttering in your chest, shortness of breath, and sudden dizziness (like you might pass out);
- high blood sugar–increased thirst, increased urination, hunger, fruity breath odor, headaches, thinking problems, blurred vision, feeling tired; or
- high blood sugar–increased thirst, increased urination, dry mouth, fruity breath odor;
- liver problems–right-sided-stomach pain, loss of appetite, unusual tiredness, itching, easy bruising or bleeding, dark urine, or yellowing of the skin or eyes.
- stomach pain, loss of appetite;
- nausea, vomiting, diarrhea;
- feeling tired; or
- weight loss.
Rare
- Diarrhea
- Increased gamma-glutamyl transpeptidase (GGT)
- Increased alkaline phosphatase
- Increased creatinine
- Nausea
- Vomiting
- Anemia
- High blood sugar (hyperglycemia)
- Fatigue
- Abdominal pain
- Increased amylase
- Decreased phosphate
- Decreased appetite
- Low white blood cell count (neutropenia)
- Cough
- Weight loss
- Constipation
- Non-cardiac chest pain
- Rash
- Back pain
- Fever
- Headache
- Low platelet count (thrombocytopenia)
- Esophageal disorder
- Increased total bilirubin
- Dizziness
- Prolonged QT interval
- Musculoskeletal pain
- Itching
Drug Interaction
| DRUG | INTERACTION |
|---|---|
| Abaloparatide | The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Ceritinib. |
| Abametapir | The serum concentration of Ceritinib can be increased when it is combined with Abametapir. |
| Abatacept | The metabolism of Ceritinib can be increased when combined with Abatacept. |
| Abemaciclib | The metabolism of Abemaciclib can be decreased when combined with Ceritinib. |
| Abrocitinib | The serum concentration of Ceritinib can be increased when it is combined with Abrocitinib. |
| Acalabrutinib | The metabolism of Acalabrutinib can be decreased when combined with Ceritinib. |
| Acarbose | The therapeutic efficacy of Acarbose can be decreased when used in combination with Ceritinib. |
| Acebutolol | Acebutolol may increase the bradycardic activities of Ceritinib. |
| Acenocoumarol | The serum concentration of Acenocoumarol can be increased when it is combined with Ceritinib. |
| Acetaminophen | The metabolism of Ceritinib can be increased when combined with Acetaminophen. |
| Acetazolamide | The metabolism of Ceritinib can be decreased when combined with Acetazolamide. |
| Acetohexamide | The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Ceritinib. |
| Acetylsalicylic acid | The metabolism of Acetylsalicylic acid can be decreased when combined with Ceritinib. |
| Acrivastine | The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Ceritinib. |
| Adalimumab | The metabolism of Ceritinib can be increased when combined with Adalimumab. |
| Adenosine | The risk or severity of QTc prolongation can be increased when Adenosine is combined with Ceritinib. |
| Afatinib | The serum concentration of Ceritinib can be increased when it is combined with Afatinib. |
| Ajmaline | The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Ceritinib. |
| Albendazole | The metabolism of Ceritinib can be decreased when combined with Albendazole. |
| Albiglutide | The therapeutic efficacy of Albiglutide can be decreased when used in combination with Ceritinib. |
| Aldesleukin | The metabolism of Ceritinib can be decreased when combined with Aldesleukin. |
| Alectinib | The metabolism of Alectinib can be decreased when combined with Ceritinib. |
| Alfentanil | Alfentanil may increase the bradycardic activities of Ceritinib. |
| Alfuzosin | The metabolism of Alfuzosin can be decreased when combined with Ceritinib. |
| Alimemazine | The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Ceritinib. |
| Alogliptin | The therapeutic efficacy of Alogliptin can be decreased when used in combination with Ceritinib. |
| Alosetron | The metabolism of Alosetron can be decreased when combined with Ceritinib. |
| Alpelisib | The metabolism of Ceritinib can be increased when combined with Alpelisib. |
| Alprazolam | The metabolism of Alprazolam can be decreased when combined with Ceritinib. |
| Amantadine | The risk or severity of QTc prolongation can be increased when Amantadine is combined with Ceritinib. |
| Ambrisentan | The serum concentration of Ceritinib can be increased when it is combined with Ambrisentan. |
| Amifampridine | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Amifampridine. |
| Aminoglutethimide | The metabolism of Ceritinib can be increased when combined with Aminoglutethimide. |
| Aminophenazone | The metabolism of Aminophenazone can be decreased when combined with Ceritinib. |
| Aminophylline | The metabolism of Aminophylline can be decreased when combined with Ceritinib. |
| Amiodarone | Amiodarone may increase the bradycardic activities of Ceritinib. |
| Amisulpride | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Amisulpride. |
| Amitriptyline | The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Ceritinib. |
| Amlodipine | Amlodipine may increase the bradycardic activities of Ceritinib. |
| Amobarbital | The metabolism of Ceritinib can be increased when combined with Amobarbital. |
| Amodiaquine | The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Ceritinib. |
| Amoxapine | The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Ceritinib. |
| Amprenavir | The metabolism of Ceritinib can be decreased when combined with Amprenavir. |
| Anagrelide | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Anagrelide. |
| Anakinra | The metabolism of Ceritinib can be increased when combined with Anakinra. |
| Antazoline | The risk or severity of QTc prolongation can be increased when Antazoline is combined with Ceritinib. |
| Antipyrine | The metabolism of Antipyrine can be decreased when combined with Ceritinib. |
| Apalutamide | The serum concentration of Ceritinib can be decreased when it is combined with Apalutamide. |
| Apixaban | The metabolism of Apixaban can be decreased when combined with Ceritinib. |
| Apomorphine | The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Ceritinib. |
| Apremilast | The metabolism of Ceritinib can be increased when combined with Apremilast. |
| Aprepitant | The metabolism of Ceritinib can be decreased when combined with Aprepitant. |
| Arformoterol | The metabolism of Arformoterol can be decreased when combined with Ceritinib. |
| Aripiprazole | The metabolism of Aripiprazole can be decreased when combined with Ceritinib. |
| Aripiprazole lauroxil | The metabolism of Aripiprazole lauroxil can be decreased when combined with Ceritinib. |
| Armodafinil | The metabolism of Ceritinib can be increased when combined with Armodafinil. |
| Arsenic trioxide | The serum concentration of Ceritinib can be increased when it is combined with Arsenic trioxide. |
| Artemether | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Artemether. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Articaine. |
| Asciminib | The serum concentration of Ceritinib can be increased when it is combined with Asciminib. |
| Asenapine | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Asenapine. |
| Astemizole | The metabolism of Astemizole can be decreased when combined with Ceritinib. |
| Asunaprevir | The serum concentration of Ceritinib can be increased when it is combined with Asunaprevir. |
| Atazanavir | The metabolism of Ceritinib can be decreased when combined with Atazanavir. |
| Atenolol | Atenolol may increase the bradycardic activities of Ceritinib. |
| Atomoxetine | The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ceritinib. |
| Atorvastatin | The metabolism of Atorvastatin can be decreased when combined with Ceritinib. |
| Atropine | The risk or severity of QTc prolongation can be increased when Atropine is combined with Ceritinib. |
| Avacopan | The metabolism of Ceritinib can be decreased when combined with Avacopan. |
| Avanafil | The serum concentration of Avanafil can be increased when it is combined with Ceritinib. |
| Avapritinib | The metabolism of Avapritinib can be decreased when combined with Ceritinib. |
| Avatrombopag | The serum concentration of Ceritinib can be increased when it is combined with Avatrombopag. |
| Axitinib | The metabolism of Axitinib can be decreased when combined with Ceritinib. |
| Azatadine | The risk or severity of QTc prolongation can be increased when Azatadine is combined with Ceritinib. |
| Azelastine | The metabolism of Azelastine can be decreased when combined with Ceritinib. |
| Azithromycin | The metabolism of Ceritinib can be decreased when combined with Azithromycin. |
| Beclomethasone | The risk or severity of hyperglycemia can be increased when Beclomethasone dipropionate is combined with Ceritinib. |
| Bedaquiline | The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Ceritinib. |
| Belantamab mafodotin | The serum concentration of Ceritinib can be increased when it is combined with Belantamab mafodotin. |
| Belinostat | The serum concentration of Ceritinib can be increased when it is combined with Belinostat. |
| Belumosudil | The serum concentration of Ceritinib can be increased when it is combined with Belumosudil. |
| Belzutifan | The serum concentration of Ceritinib can be decreased when it is combined with Belzutifan. |
| Bendamustine | The serum concentration of Bendamustine can be increased when it is combined with Ceritinib. |
| Bendroflumethiazide | Bendroflumethiazide may increase the bradycardic activities of Ceritinib. |
| Benzatropine | The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Ceritinib. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Benzocaine. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Benzyl alcohol. |
| Bepridil | Bepridil may increase the bradycardic activities of Ceritinib. |
| Beractant | Beractant may increase the bradycardic activities of Ceritinib. |
| Berotralstat | The serum concentration of Ceritinib can be increased when it is combined with Berotralstat. |
| Betamethasone | The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Ceritinib. |
| Betamethasone | The risk or severity of hyperglycemia can be increased when Betamethasone phosphate is combined with Ceritinib. |
| Betaxolol | Betaxolol may increase the bradycardic activities of Ceritinib. |
| Betrixaban | The serum concentration of Ceritinib can be increased when it is combined with Betrixaban. |
| Bexarotene | The metabolism of Ceritinib can be increased when combined with Bexarotene. |
| Bicalutamide | The metabolism of Ceritinib can be decreased when combined with Bicalutamide. |
| Bifonazole | The metabolism of Ceritinib can be decreased when combined with Bifonazole. |
| Bilastine | The risk or severity of QTc prolongation can be increased when Bilastine is combined with Ceritinib. |
| Bimekizumab | The metabolism of Ceritinib can be increased when combined with Bimekizumab. |
| Binimetinib | The serum concentration of Binimetinib can be increased when it is combined with Ceritinib. |
| Bisoprolol | Bisoprolol may increase the bradycardic activities of Ceritinib. |
| Boceprevir | The metabolism of Ceritinib can be decreased when combined with Boceprevir. |
| Bortezomib | The metabolism of Bortezomib can be decreased when combined with Ceritinib. |
| Bosentan | The metabolism of Ceritinib can be increased when combined with Bosentan. |
| Bosutinib | The metabolism of Bosutinib can be decreased when combined with Ceritinib. |
| Brentuximab vedotin | The metabolism of Brentuximab vedotin can be decreased when combined with Ceritinib. |
| Bretylium | Bretylium may increase the bradycardic activities of Ceritinib. |
| Brigatinib | The metabolism of Brigatinib can be decreased when combined with Ceritinib. |
| Brivaracetam | The metabolism of Brivaracetam can be decreased when combined with Ceritinib. |
| Bromocriptine | The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Ceritinib. |
| Brompheniramine | The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Ceritinib. |
| Buclizine | The risk or severity of QTc prolongation can be increased when Buclizine is combined with Ceritinib. |
| Budesonide | The risk or severity of hyperglycemia can be increased when Budesonide is combined with Ceritinib. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Bupivacaine. |
| Buprenorphine | The metabolism of Ceritinib can be decreased when combined with Buprenorphine. |
| Bupropion | The metabolism of Bupropion can be decreased when combined with Ceritinib. |
| Buserelin | The risk or severity of QTc prolongation can be increased when Buserelin is combined with Ceritinib. |
| Busulfan | The metabolism of Busulfan can be decreased when combined with Ceritinib. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Butacaine. |
| Butalbital | The metabolism of Ceritinib can be increased when combined with Butalbital. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Butamben. |
| Butriptyline | The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Ceritinib. |
| Cabazitaxel | The metabolism of Cabazitaxel can be decreased when combined with Ceritinib. |
| Cabergoline | The metabolism of Cabergoline can be decreased when combined with Ceritinib. |
| Cabozantinib | The metabolism of Cabozantinib can be decreased when combined with Ceritinib. |
| Calcitriol | The metabolism of Ceritinib can be increased when combined with Calcitriol. |
| Calfactant | Calfactant may increase the bradycardic activities of Ceritinib. |
| Canagliflozin | The serum concentration of Ceritinib can be increased when it is combined with Canagliflozin. |
| Canakinumab | The metabolism of Ceritinib can be increased when combined with Canakinumab. |
| Candesartan cilexetil | The metabolism of Candesartan cilexetil can be decreased when combined with Ceritinib. |
| Candicidin | The metabolism of Ceritinib can be decreased when combined with Candicidin. |
| Cannabidiol | The metabolism of Ceritinib can be decreased when combined with Cannabidiol. |
| Capecitabine | The metabolism of Capecitabine can be decreased when combined with Ceritinib. |
| Capmatinib | The serum concentration of Ceritinib can be increased when it is combined with Capmatinib. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Capsaicin. |
| Carbamazepine | The metabolism of Ceritinib can be increased when combined with Carbamazepine. |
| Carbimazole | The therapeutic efficacy of Carbimazole can be decreased when used in combination with Ceritinib. |
| Carbinoxamine | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Ceritinib. |
| Carfilzomib | The serum concentration of Ceritinib can be increased when it is combined with Carfilzomib. |
| Carvedilol | Carvedilol may increase the bradycardic activities of Ceritinib. |
| Cefradine | The metabolism of Ceritinib can be increased when combined with Cefradine. |
| Celecoxib | The metabolism of Celecoxib can be decreased when combined with Ceritinib. |
| Celiprolol | Celiprolol may increase the bradycardic activities of Ceritinib. |
| Cenobamate | The serum concentration of Ceritinib can be decreased when it is combined with Cenobamate. |
| Cephalexin | The metabolism of Ceritinib can be decreased when combined with Cephalexin. |
| Cerivastatin | The metabolism of Ceritinib can be increased when combined with Cerivastatin. |
| Certolizumab pegol | The metabolism of Ceritinib can be increased when combined with Certolizumab pegol. |
| Cetirizine | The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Ceritinib. |
| Chloramphenicol | The metabolism of Ceritinib can be decreased when combined with Chloramphenicol. |
| Chlorcyclizine | The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Ceritinib. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Chloroprocaine. |
| Chloroquine | The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Ceritinib. |
| Chlorpheniramine | The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Ceritinib. |
| Chlorpromazine | The metabolism of Ceritinib can be increased when combined with Chlorpromazine. |
| Chlorpropamide | The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ceritinib. |
| Chlorprothixene | The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Ceritinib. |
| Ciclesonide | The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Ceritinib. |
| Cilostazol | The metabolism of Cilostazol can be decreased when combined with Ceritinib. |
| Cimetidine | The metabolism of Ceritinib can be decreased when combined with Cimetidine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Cinchocaine. |
| Cinnarizine | Cinnarizine may increase the bradycardic activities of Ceritinib. |
| Cinoxacin | The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Ceritinib. |
| Ciprofloxacin | The metabolism of Ceritinib can be decreased when combined with Ciprofloxacin. |
| Cisapride | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Cisapride. |
| Citalopram | The metabolism of Ceritinib can be decreased when combined with Citalopram. |
| Clarithromycin | The metabolism of Ceritinib can be decreased when combined with Clarithromycin. |
| Clemastine | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Clemastine. |
| Clevidipine | Clevidipine may increase the bradycardic activities of Ceritinib. |
| Clobazam | The metabolism of Ceritinib can be increased when combined with Clobazam. |
| Clobetasol | The risk or severity of hyperglycemia can be increased when Clobetasol propionate is combined with Ceritinib. |
| Clofazimine | The serum concentration of Ceritinib can be increased when it is combined with Clofazimine. |
| Clofibrate | The metabolism of Ceritinib can be increased when combined with Clofibrate. |
| Clomifene | The serum concentration of Ceritinib can be increased when it is combined with Clomifene. |
| Clomipramine | The metabolism of Clomipramine can be decreased when combined with Ceritinib. |
| Clonidine | Clonidine may increase the bradycardic activities of Ceritinib. |
| Clopidogrel | The metabolism of Clopidogrel can be decreased when combined with Ceritinib. |
| Clozapine | The metabolism of Ceritinib can be increased when combined with Clozapine. |
| Cobicistat | The metabolism of Ceritinib can be decreased when combined with Cobicistat. |
| Cobimetinib | The metabolism of Cobimetinib can be decreased when combined with Ceritinib. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Cocaine. |
| Colchicine | The metabolism of Colchicine can be decreased when combined with Ceritinib. |
| Conivaptan | The metabolism of Ceritinib can be decreased when combined with Conivaptan. |
| Copanlisib | The metabolism of Copanlisib can be decreased when combined with Ceritinib. |
| Corticotropin | The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Ceritinib. |
| Cortisone acetate | The risk or severity of hyperglycemia can be increased when Cortisone acetate is combined with Ceritinib. |
| Crizotinib | Crizotinib may increase the bradycardic activities of Ceritinib. |
| Curcumin | The metabolism of Ceritinib can be decreased when combined with Curcumin. |
| Cyclandelate | Cyclandelate may increase the bradycardic activities of Ceritinib. |
| Cyclizine | The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Ceritinib. |
| Cyclophosphamide | The metabolism of Ceritinib can be increased when combined with Cyclophosphamide. |
| Cyclosporine | The serum concentration of Ceritinib can be increased when it is combined with Cyclosporine. |
| Cyproheptadine | The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Ceritinib. |
| Cyproterone acetate | The metabolism of Ceritinib can be decreased when combined with Cyproterone acetate. |
| Dabigatran etexilate | The serum concentration of Ceritinib can be increased when it is combined with Dabigatran etexilate. |
| Dabrafenib | The serum concentration of Ceritinib can be decreased when it is combined with Dabrafenib. |
| Daclatasvir | The serum concentration of Ceritinib can be increased when it is combined with Daclatasvir. |
| Dacomitinib | The serum concentration of Ceritinib can be increased when it is combined with Dacomitinib. |
| Dactinomycin | The serum concentration of Ceritinib can be increased when it is combined with Dactinomycin. |
| Dalfopristin | The metabolism of Ceritinib can be decreased when combined with Dalfopristin. |
| Danazol | The metabolism of Ceritinib can be decreased when combined with Danazol. |
| Dapagliflozin | The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Ceritinib. |
| Dapsone | The metabolism of Dapsone can be decreased when combined with Ceritinib. |
| Daptomycin | The serum concentration of Ceritinib can be increased when it is combined with Daptomycin. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ceritinib. |
| Darolutamide | The serum concentration of Ceritinib can be increased when it is combined with Darolutamide. |
| Darunavir | The serum concentration of Ceritinib can be increased when it is combined with Darunavir. |
| Dasabuvir | The serum concentration of Ceritinib can be increased when it is combined with Dasabuvir. |
| Dasatinib | The metabolism of Ceritinib can be decreased when combined with Dasatinib. |
| Daunorubicin | The metabolism of Ceritinib can be decreased when combined with Daunorubicin. |
| Deferasirox | The metabolism of Ceritinib can be increased when combined with Deferasirox. |
| Deflazacort | The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Ceritinib. |
| Degarelix | The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ceritinib. |
| Delafloxacin | The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Ceritinib. |
| Delamanid | Ceritinib may increase the QTc-prolonging activities of Delamanid. |
| Delavirdine | The metabolism of Ceritinib can be decreased when combined with Delavirdine. |
| Desflurane | The risk or severity of QTc prolongation can be increased when Desflurane is combined with Ceritinib. |
| Desipramine | The metabolism of Ceritinib can be decreased when combined with Desipramine. |
| Desloratadine | The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Ceritinib. |
| Desogestrel | The metabolism of Desogestrel can be decreased when combined with Ceritinib. |
| Desoximetasone | The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Ceritinib. |
| Desvenlafaxine | The metabolism of Ceritinib can be decreased when combined with Desvenlafaxine. |
| Deutetrabenazine | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Deutetrabenazine. |
| Dexamethasone | The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Ceritinib. |
| Dexamethasone acetate | The risk or severity of hyperglycemia can be increased when Dexamethasone acetate is combined with Ceritinib. |
| Dexbrompheniramine | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ceritinib. |
| Dexchlorpheniramine | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Dexchlorpheniramine maleate. |
| Dexibuprofen | The metabolism of Dexibuprofen can be decreased when combined with Ceritinib. |
| Dexmedetomidine | Dexmedetomidine may increase the bradycardic activities of Ceritinib. |
| Dextromethorphan | The metabolism of Dextromethorphan can be decreased when combined with Ceritinib. |
| Dextropropoxyphene | The metabolism of Ceritinib can be decreased when combined with Dextropropoxyphene. |
| Diazepam | The metabolism of Diazepam can be decreased when combined with Ceritinib. |
| Diclofenac | The metabolism of Diclofenac can be decreased when combined with Ceritinib. |
| Dicloxacillin | The metabolism of Ceritinib can be increased when combined with Dicloxacillin. |
| Dicoumarol | The metabolism of Dicoumarol can be decreased when combined with Ceritinib. |
| Diethylstilbestrol | The metabolism of Ceritinib can be decreased when combined with Diethylstilbestrol. |
| Difluocortolone | The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Ceritinib. |
| Digitoxin | The metabolism of Digitoxin can be decreased when combined with Ceritinib. |
| Digoxin | Digoxin may increase the bradycardic activities of Ceritinib. |
| Dihydroergocornine | The metabolism of Ceritinib can be decreased when combined with Dihydroergocornine. |
| Dihydroergocristine | The metabolism of Ceritinib can be decreased when combined with Dihydroergocristine. |
| Dihydroergotamine | The metabolism of Dihydroergotamine can be decreased when combined with Ceritinib. |
| Diltiazem | Diltiazem may increase the bradycardic activities of Ceritinib. |
| Dimenhydrinate | The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Ceritinib. |
| Dimethyl sulfoxide | The metabolism of Ceritinib can be decreased when combined with Dimethyl sulfoxide. |
| Diosmin | The serum concentration of Ceritinib can be increased when it is combined with Diosmin. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Diphenhydramine. |
| Disopyramide | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Disopyramide. |
| Disulfiram | The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Ceritinib. |
| Docetaxel | The metabolism of Docetaxel can be decreased when combined with Ceritinib. |
| Doconexent | The metabolism of Doconexent can be decreased when combined with Ceritinib. |
| Dofetilide | The metabolism of Dofetilide can be decreased when combined with Ceritinib. |
| Dolasetron | The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Ceritinib. |
| Dolutegravir | The serum concentration of Ceritinib can be increased when it is combined with Dolutegravir. |
| Domperidone | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Domperidone. |
| Donepezil | Donepezil may increase the bradycardic activities of Ceritinib. |
| Dosulepin | The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Ceritinib. |
| Doxazosin | The metabolism of Ceritinib can be decreased when combined with Doxazosin. |
| Doxepin | The metabolism of Doxepin can be decreased when combined with Ceritinib. |
| Doxorubicin | The metabolism of Doxorubicin can be decreased when combined with Ceritinib. |
| Doxylamine | The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ceritinib. |
| Dronabinol | The serum concentration of Dronabinol can be increased when it is combined with Ceritinib. |
| Dronedarone | Dronedarone may increase the bradycardic activities of Ceritinib. |
| Droperidol | The risk or severity of QTc prolongation can be increased when Droperidol is combined with Ceritinib. |
| Drospirenone | The metabolism of Ceritinib can be decreased when combined with Drospirenone. |
| Dulaglutide | The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Ceritinib. |
| Duloxetine | The metabolism of Duloxetine can be decreased when combined with Ceritinib. |
| Duvelisib | The metabolism of Ceritinib can be decreased when combined with Duvelisib. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Dyclonine. |
| Ebastine | The metabolism of Ceritinib can be decreased when combined with Ebastine. |
| Echinacea | The metabolism of Ceritinib can be increased when combined with Echinacea. |
| Edoxaban | The serum concentration of Ceritinib can be increased when it is combined with Edoxaban. |
| Efavirenz | The metabolism of Ceritinib can be decreased when combined with Efavirenz. |
| Elagolix | The serum concentration of Ceritinib can be increased when it is combined with Elagolix. |
| Elbasvir | The serum concentration of Ceritinib can be increased when it is combined with Elbasvir. |
| Eletriptan | The metabolism of Eletriptan can be decreased when combined with Ceritinib. |
| Elexacaftor | The metabolism of Ceritinib can be decreased when combined with Elexacaftor. |
| Eliglustat | The metabolism of Eliglustat can be decreased when combined with Ceritinib. |
| Elvitegravir | The metabolism of Ceritinib can be decreased when combined with Elvitegravir. |
| Emapalumab | The metabolism of Ceritinib can be increased when combined with Emapalumab. |
| Emedastine | The risk or severity of QTc prolongation can be increased when Emedastine is combined with Ceritinib. |
| Empagliflozin | The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ceritinib. |
| Enasidenib | The serum concentration of Ceritinib can be increased when it is combined with Enasidenib. |
| Encainide | The risk or severity of QTc prolongation can be increased when Encainide is combined with Ceritinib. |
| Encorafenib | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Encorafenib. |
| Enfortumab vedotin | The serum concentration of Ceritinib can be increased when it is combined with Enfortumab vedotin. |
| Enoxacin | The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Ceritinib. |
| Entrectinib | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Entrectinib. |
| Enzalutamide | The serum concentration of Ceritinib can be decreased when it is combined with Enzalutamide. |
| Epinastine | The risk or severity of QTc prolongation can be increased when Epinastine is combined with Ceritinib. |
| Epinephrine | The metabolism of Ceritinib can be decreased when combined with Epinephrine. |
| Erdafitinib | The serum concentration of Ceritinib can be increased when it is combined with Erdafitinib. |
| Ergotamine | The metabolism of Ceritinib can be decreased when combined with Ergotamine. |
| Eribulin | The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ceritinib. |
| Erlotinib | The metabolism of Erlotinib can be decreased when combined with Ceritinib. |
| Ertugliflozin | The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Ceritinib. |
| Erythromycin | The serum concentration of Ceritinib can be increased when it is combined with Erythromycin. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ceritinib. |
| Escitalopram | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Escitalopram. |
| Esketamine | The metabolism of Ceritinib can be increased when combined with Esketamine. |
| Eslicarbazepine | The metabolism of Ceritinib can be increased when combined with Eslicarbazepine. |
| Esmolol | Esmolol may increase the bradycardic activities of Ceritinib. |
| Estetrol | The metabolism of Ceritinib can be decreased when combined with Estetrol. |
| Estradiol | The metabolism of Estradiol can be decreased when combined with Ceritinib. |
| Estradiol acetate | The metabolism of Ceritinib can be increased when combined with Estradiol acetate. |
| Estradiol benzoate | The metabolism of Ceritinib can be increased when combined with Estradiol benzoate. |
| Estradiol cypionate | The metabolism of Ceritinib can be increased when combined with Estradiol cypionate. |
| Estradiol | The metabolism of Ceritinib can be increased when combined with Estradiol dienanthate. |
| Estradiol valerate | The metabolism of Ceritinib can be increased when combined with Estradiol valerate. |
| Estrone sulfate | The metabolism of Estrone sulfate can be decreased when combined with Ceritinib. |
| Eszopiclone | The metabolism of Eszopiclone can be decreased when combined with Ceritinib. |
| Etanercept | The metabolism of Ceritinib can be increased when combined with Etanercept. |
| Ethambutol | The metabolism of Ceritinib can be decreased when combined with Ethambutol. |
| Ethanol | The metabolism of Ceritinib can be increased when combined with Ethanol. |
| Ethinylestradiol | The metabolism of Ethinylestradiol can be decreased when combined with Ceritinib. |
| Ethosuximide | Ethosuximide may increase the bradycardic activities of Ceritinib. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Ethyl chloride. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Etidocaine. |
| Etodolac | The metabolism of Etodolac can be decreased when combined with Ceritinib. |
| Etoposide | The metabolism of Etoposide can be decreased when combined with Ceritinib. |
| Etoricoxib | The metabolism of Ceritinib can be decreased when combined with Etoricoxib. |
| Etravirine | The metabolism of Ceritinib can be increased when combined with Etravirine. |
| Everolimus | The serum concentration of Ceritinib can be increased when it is combined with Everolimus. |
| Exenatide | The therapeutic efficacy of Exenatide can be decreased when used in combination with Ceritinib. |
| Ezogabine | The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Ceritinib. |
| Famotidine | The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ceritinib. |
| Favipiravir | The serum concentration of Ceritinib can be increased when it is combined with Favipiravir. |
| Fedratinib | The serum concentration of Ceritinib can be increased when it is combined with Fedratinib. |
| Felbamate | The metabolism of Ceritinib can be increased when combined with Felbamate. |
| Felodipine | Felodipine may increase the bradycardic activities of Ceritinib. |
| Fenofibrate | The metabolism of Ceritinib can be decreased when combined with Fenofibrate. |
| Fentanyl | The metabolism of Fentanyl can be decreased when combined with Ceritinib. |
| Fexinidazole | The risk or severity of adverse effects can be increased when Ceritinib is combined with Fexinidazole. |
| Fexofenadine | The serum concentration of Ceritinib can be increased when it is combined with Fexofenadine. |
| Filgotinib | The serum concentration of Ceritinib can be increased when it is combined with Filgotinib. |
| Finerenone | The serum concentration of Finerenone can be increased when it is combined with Ceritinib. |
| Fingolimod | Fingolimod may increase the bradycardic activities of Ceritinib. |
| Flecainide | The risk or severity of QTc prolongation can be increased when Flecainide is combined with Ceritinib. |
| Flibanserin | The serum concentration of Ceritinib can be increased when it is combined with Flibanserin. |
| Flucloxacillin | The metabolism of Ceritinib can be increased when combined with Flucloxacillin. |
| Fluconazole | The serum concentration of Ceritinib can be increased when it is combined with Fluconazole. |
| Fludrocortisone | The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Ceritinib. |
| Fluindione | The metabolism of Fluindione can be decreased when combined with Ceritinib. |
| Flumethasone | The risk or severity of hyperglycemia can be increased when Flumethasone is combined with Ceritinib. |
| Flunarizine | Flunarizine may increase the bradycardic activities of Ceritinib. |
| Flunisolide | The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Ceritinib. |
| Flunitrazepam | The metabolism of Flunitrazepam can be decreased when combined with Ceritinib. |
| Fluocinolone | The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Ceritinib. |
| Fluocinonide | The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Ceritinib. |
| Fluocortolone | The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Ceritinib. |
| Fluorometholone | The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Ceritinib. |
| Fluorouracil | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Ceritinib. |
| Fluoxetine | The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Ceritinib. |
| Flupentixol | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Flupentixol. |
| Fluprednisolone | The risk or severity of hyperglycemia can be increased when Fluprednisolone is combined with Ceritinib. |
| Flurbiprofen | The metabolism of Flurbiprofen can be decreased when combined with Ceritinib. |
| Fluspirilene | Fluspirilene may increase the bradycardic activities of Ceritinib. |
| Fluticasone | The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Ceritinib. |
| Fluticasone furoate | The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Ceritinib. |
| Fluticasone | The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Ceritinib. |
| Fluvastatin | The metabolism of Fluvastatin can be decreased when combined with Ceritinib. |
| Fluvoxamine | The metabolism of Ceritinib can be decreased when combined with Fluvoxamine. |
| Follitropin | The therapeutic efficacy of Follitropin can be decreased when used in combination with Ceritinib. |
| Formestane | The metabolism of Ceritinib can be increased when combined with Formestane. |
| Formoterol | The metabolism of Formoterol can be decreased when combined with Ceritinib. |
| Fosamprenavir | The metabolism of Ceritinib can be decreased when combined with Fosamprenavir. |
| Fosaprepitant | The metabolism of Ceritinib can be increased when combined with Fosaprepitant. |
| Foscarnet | The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Ceritinib. |
| Fosnetupitant | The metabolism of Ceritinib can be decreased when combined with Fosnetupitant. |
| Fosphenytoin | The metabolism of Ceritinib can be increased when combined with Fosphenytoin. |
| Fostamatinib | The metabolism of Ceritinib can be decreased when combined with Fostamatinib. |
| Fostemsavir | The serum concentration of Ceritinib can be increased when it is combined with Fostemsavir. |
| Fusidic acid | The metabolism of Ceritinib can be decreased when combined with Fusidic acid. |
| Futibatinib | The serum concentration of Ceritinib can be increased when it is combined with Futibatinib. |
| Gadobenic acid | The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Ceritinib. |
| Galantamine | Galantamine may increase the bradycardic activities of Ceritinib. |
| Gatifloxacin | The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Ceritinib. |
| Gemcitabine | The serum concentration of Ceritinib can be increased when it is combined with Gemcitabine. |
| Gemifloxacin | The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Ceritinib. |
| Gilteritinib | The metabolism of Ceritinib can be decreased when combined with Gilteritinib. |
| Ginkgo biloba | The metabolism of Ceritinib can be decreased when combined with Ginkgo biloba. |
| Glasdegib | The serum concentration of Ceritinib can be increased when it is combined with Glasdegib. |
| Glecaprevir | The serum concentration of Ceritinib can be increased when it is combined with Glecaprevir. |
| Gliclazide | The therapeutic efficacy of Gliclazide can be decreased when used in combination with Ceritinib. |
| Glimepiride | The therapeutic efficacy of Glimepiride can be decreased when used in combination with Ceritinib. |
| Glipizide | The therapeutic efficacy of Glipizide can be decreased when used in combination with Ceritinib. |
| Gliquidone | The therapeutic efficacy of Gliquidone can be decreased when used in combination with Ceritinib. |
| Glyburide | The metabolism of Ceritinib can be decreased when combined with Glyburide. |
| Glycerol | The metabolism of Ceritinib can be increased when combined with Glycerol phenylbutyrate. |
| Glymidine | The therapeutic efficacy of Glymidine can be decreased when used in combination with Ceritinib. |
| Golimumab | The metabolism of Ceritinib can be increased when combined with Golimumab. |
| Goserelin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ceritinib. |
| Granisetron | The risk or severity of QTc prolongation can be increased when Granisetron is combined with Ceritinib. |
| Grazoprevir | The serum concentration of Ceritinib can be increased when it is combined with Grazoprevir. |
| Grepafloxacin | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Grepafloxacin. |
| Griseofulvin | The metabolism of Ceritinib can be increased when combined with Griseofulvin. |
| Guanfacine | Guanfacine may increase the bradycardic activities of Ceritinib. |
| Halofantrine | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Halofantrine. |
| Haloperidol | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Haloperidol. |
| Halothane | The metabolism of Halothane can be decreased when combined with Ceritinib. |
| Hydralazine | The metabolism of Ceritinib can be decreased when combined with Hydralazine. |
| Hydrochlorothiazide | The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Ceritinib. |
| Hydrocortamate | The metabolism of Ceritinib can be increased when combined with Hydrocortamate. |
| Hydrocortisone | The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Ceritinib. |
| Hydrocortisone acetate | The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Ceritinib. |
| Hydrocortisone butyrate | The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Ceritinib. |
| Hydrocortisone | The risk or severity of hyperglycemia can be increased when Hydrocortisone cypionate is combined with Ceritinib. |
| Hydrocortisone | The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Ceritinib. |
| Hydromorphone | The metabolism of Hydromorphone can be decreased when combined with Ceritinib. |
| Hydroxychloroquine | The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Ceritinib. |
| Hydroxyzine | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Hydroxyzine. |
| Hyoscyamine | The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Ceritinib. |
| Ibandronate | The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ceritinib. |
| Ibrutinib | The metabolism of Ibrutinib can be decreased when combined with Ceritinib. |
| Ibuprofen | The metabolism of Ibuprofen can be decreased when combined with Ceritinib. |
| Ibutilide | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Ibutilide. |
| Idarubicin | The metabolism of Idarubicin can be decreased when combined with Ceritinib. |
| Idelalisib | The metabolism of Idelalisib can be decreased when combined with Ceritinib. |
| Ifosfamide | The metabolism of Ceritinib can be increased when combined with Ifosfamide. |
| Iloperidone | The metabolism of Iloperidone can be decreased when combined with Ceritinib. |
| Imatinib | The serum concentration of Ceritinib can be increased when it is combined with Imatinib. |
| Imipramine | The risk or severity of QTc prolongation can be increased when Imipramine is combined with Ceritinib. |
| Indacaterol | The serum concentration of Ceritinib can be increased when it is combined with Indacaterol. |
| Indapamide | The risk or severity of QTc prolongation can be increased when Indapamide is combined with Ceritinib. |
| Indinavir | The metabolism of Ceritinib can be decreased when combined with Indinavir. |
| Indomethacin | The metabolism of Indomethacin can be decreased when combined with Ceritinib. |
| Infigratinib | The metabolism of Ceritinib can be decreased when combined with Infigratinib. |
| Infliximab | The metabolism of Ceritinib can be increased when combined with Infliximab. |
| Inotersen | The risk or severity of QTc prolongation can be increased when Inotersen is combined with Ceritinib. |
| Inotuzumab | The serum concentration of Ceritinib can be increased when it is combined with Inotuzumab ozogamicin. |
| Insulin aspart | The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Ceritinib. |
| Insulin beef | The therapeutic efficacy of Insulin beef can be decreased when used in combination with Ceritinib. |
| Insulin degludec | The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Ceritinib. |
| Insulin detemir | The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Ceritinib. |
| Insulin glargine | The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Ceritinib. |
| Insulin glulisine | The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Ceritinib. |
| Insulin human | The therapeutic efficacy of Insulin human can be decreased when used in combination with Ceritinib. |
| Insulin lispro | The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Ceritinib. |
| Insulin pork | The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ceritinib. |
| Irbesartan | The metabolism of Ceritinib can be decreased when combined with Irbesartan. |
| Irinotecan | The metabolism of Irinotecan can be decreased when combined with Ceritinib. |
| Isavuconazole | The serum concentration of Ceritinib can be increased when it is combined with Isavuconazole. |
| Isavuconazonium | The serum concentration of Ceritinib can be increased when it is combined with Isavuconazonium. |
| Isoflurane | The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Ceritinib. |
| Isoniazid | The metabolism of Ceritinib can be decreased when combined with Isoniazid. |
| Isradipine | Isradipine may increase the bradycardic activities of Ceritinib. |
| Istradefylline | The serum concentration of Ceritinib can be increased when it is combined with Istradefylline. |
| Itraconazole | The metabolism of Ceritinib can be decreased when combined with Itraconazole. |
| Ivabradine | Ivabradine may increase the bradycardic activities of Ceritinib. |
| Ivacaftor | The serum concentration of Ceritinib can be increased when it is combined with Ivacaftor. |
| Ivosidenib | The metabolism of Ceritinib can be increased when combined with Ivosidenib. |
| Ixabepilone | The serum concentration of Ceritinib can be increased when it is combined with Ixabepilone. |
| Ixazomib | The metabolism of Ixazomib can be decreased when combined with Ceritinib. |
| Ketamine | The metabolism of Ketamine can be decreased when combined with Ceritinib. |
| Ketazolam | The metabolism of Ceritinib can be decreased when combined with Ketazolam. |
| Ketoconazole | The metabolism of Ceritinib can be decreased when combined with Ketoconazole. |
| Ketorolac | The metabolism of Ketorolac can be decreased when combined with Ceritinib. |
| Labetalol | Labetalol may increase the bradycardic activities of Ceritinib. |
| Lacidipine | Lacidipine may increase the bradycardic activities of Ceritinib. |
| Lacosamide | Lacosamide may increase the bradycardic activities of Ceritinib. |
| Lamotrigine | Lamotrigine may increase the bradycardic activities of Ceritinib. |
| Lanreotide | Lanreotide may increase the bradycardic activities of Ceritinib. |
| Lansoprazole | The metabolism of Lansoprazole can be decreased when combined with Ceritinib. |
| Lapatinib | The serum concentration of Ceritinib can be increased when it is combined with Lapatinib. |
| Larotrectinib | The serum concentration of Ceritinib can be increased when it is combined with Larotrectinib. |
| Lasmiditan | The serum concentration of Ceritinib can be increased when it is combined with Lasmiditan. |
| Ledipasvir | The serum concentration of Ceritinib can be increased when it is combined with Ledipasvir. |
| Lefamulin | Lefamulin may increase the QTc-prolonging activities of Ceritinib. |
| Leflunomide | The metabolism of Leflunomide can be decreased when combined with Ceritinib. |
| Lemborexant | The serum concentration of Ceritinib can be increased when it is combined with Lemborexant. |
| Lenvatinib | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Lenvatinib. |
| Lercanidipine | Lercanidipine may increase the bradycardic activities of Ceritinib. |
| Lesinurad | The metabolism of Ceritinib can be increased when combined with Lesinurad. |
| Letermovir | The metabolism of Ceritinib can be decreased when combined with Letermovir. |
| Leuprolide | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ceritinib. |
| Levacetylmethadol | The metabolism of Levacetylmethadol can be decreased when combined with Ceritinib. |
| Levamlodipine | The serum concentration of Levamlodipine can be increased when it is combined with Ceritinib. |
| Levobetaxolol | Levobetaxolol may increase the bradycardic activities of Ceritinib. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Levobupivacaine. |
| Levocabastine | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Ceritinib. |
| Levocetirizine | The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Ceritinib. |
| Levofloxacin | The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Ceritinib. |
| Levoketoconazole | The metabolism of Ceritinib can be decreased when combined with Levoketoconazole. |
| Levomenthol | Levomenthol may increase the bradycardic activities of Ceritinib. |
| Levosimendan | The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Ceritinib. |
| Levothyroxine | The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Ceritinib. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Lidocaine. |
| Lidoflazine | Lidoflazine may increase the bradycardic activities of Ceritinib. |
| Linagliptin | The serum concentration of Ceritinib can be increased when it is combined with Linagliptin. |
| Liothyronine | The therapeutic efficacy of Liothyronine can be decreased when used in combination with Ceritinib. |
| Liotrix | The therapeutic efficacy of Liotrix can be decreased when used in combination with Ceritinib. |
| Liraglutide | The therapeutic efficacy of Liraglutide can be decreased when used in combination with Ceritinib. |
| Lixisenatide | The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Ceritinib. |
| Lofexidine | The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Ceritinib. |
| Lomefloxacin | The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Ceritinib. |
| Lomitapide | The metabolism of Lomitapide can be decreased when combined with Ceritinib. |
| Lonafarnib | The metabolism of Ceritinib can be decreased when combined with Lonafarnib. |
| Loncastuximab | The serum concentration of Ceritinib can be increased when it is combined with Loncastuximab tesirine. |
| Loperamide | Loperamide may increase the bradycardic activities of Ceritinib. |
| Nitrendipine | Nitrendipine may increase the bradycardic activities of Ceritinib. |
| Norethisterone | The metabolism of Ceritinib can be decreased when combined with Norethisterone. |
| Norfloxacin | The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Ceritinib. |
| Norgestimate | The serum concentration of Ceritinib can be increased when it is combined with Norgestimate. |
| Nortriptyline | The metabolism of Nortriptyline can be decreased when combined with Ceritinib. |
| Noscapine | The metabolism of Ceritinib can be decreased when combined with Noscapine. |
| Nylidrin | Nylidrin may increase the bradycardic activities of Ceritinib. |
| Octreotide | Octreotide may increase the bradycardic activities of Ceritinib. |
| Ofloxacin | The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Ceritinib. |
| Olanzapine | The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Ceritinib. |
| Olaparib | The metabolism of Olaparib can be decreased when combined with Ceritinib. |
| Olodaterol | The metabolism of Olodaterol can be decreased when combined with Ceritinib. |
| Omadacycline | The serum concentration of Ceritinib can be increased when it is combined with Omadacycline. |
| Ombitasvir | The serum concentration of Ceritinib can be increased when it is combined with Ombitasvir. |
| Omeprazole | The metabolism of Ceritinib can be increased when combined with Omeprazole. |
| Ondansetron | The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Ceritinib. |
| Oritavancin | The metabolism of Ceritinib can be increased when combined with Oritavancin. |
| Orphenadrine | The metabolism of Ceritinib can be decreased when combined with Orphenadrine. |
| Osilodrostat | The metabolism of Ceritinib can be decreased when combined with Osilodrostat. |
| Osimertinib | The metabolism of Osimertinib can be decreased when combined with Ceritinib. |
| Ospemifene | The metabolism of Ospemifene can be decreased when combined with Ceritinib. |
| Oxaliplatin | The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ceritinib. |
| Oxatomide | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Oxatomide. |
| Oxcarbazepine | The metabolism of Ceritinib can be increased when combined with Oxcarbazepine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Oxetacaine. |
| Oxprenolol | Oxprenolol may increase the bradycardic activities of Ceritinib. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Oxybuprocaine. |
| Oxybutynin | The metabolism of Ceritinib can be decreased when combined with Oxybutynin. |
| Oxytocin | The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ceritinib. |
| Paclitaxel | The metabolism of Ceritinib can be increased when combined with Paclitaxel. |
| Pacritinib | The serum concentration of Ceritinib can be increased when it is combined with Pacritinib. |
| Palbociclib | The serum concentration of Ceritinib can be increased when it is combined with Palbociclib. |
| Paliperidone | The serum concentration of Ceritinib can be increased when it is combined with Paliperidone. |
| Panobinostat | The metabolism of Panobinostat can be decreased when combined with Ceritinib. |
| Papaverine | The risk or severity of QTc prolongation can be increased when Papaverine is combined with Ceritinib. |
| Paramethadione | The metabolism of Paramethadione can be decreased when combined with Ceritinib. |
| Parathyroid | The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Ceritinib. |
| Parecoxib | The metabolism of Parecoxib can be decreased when combined with Ceritinib. |
| Paritaprevir | The serum concentration of Ceritinib can be increased when it is combined with Paritaprevir. |
| Pasireotide | Pasireotide may increase the bradycardic activities of Ceritinib. |
| Pazopanib | The metabolism of Ceritinib can be decreased when combined with Pazopanib. |
| Pefloxacin | The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Ceritinib. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Ceritinib. |
| Penbutolol | Penbutolol may increase the bradycardic activities of Ceritinib. |
| Pentamidine | The therapeutic efficacy of Pentamidine can be decreased when used in combination with Ceritinib. |
| Pentobarbital | The metabolism of Ceritinib can be increased when combined with Pentobarbital. |
| Perampanel | The metabolism of Ceritinib can be increased when combined with Perampanel. |
| Perflutren | The risk or severity of QTc prolongation can be increased when Perflutren is combined with Ceritinib. |
| Perhexiline | Perhexiline may increase the bradycardic activities of Ceritinib. |
| Pexidartinib | The metabolism of Pexidartinib can be decreased when combined with Ceritinib. |
| Phenformin | The therapeutic efficacy of Phenformin can be decreased when used in combination with Ceritinib. |
| Pheniramine | The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Ceritinib. |
| Phenobarbital | The metabolism of Ceritinib can be increased when combined with Phenobarbital. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Phenol. |
| Phenprocoumon | The metabolism of Phenprocoumon can be decreased when combined with Ceritinib. |
| Phenylbutazone | The metabolism of Ceritinib can be increased when combined with Phenylbutazone. |
| Phenytoin | The metabolism of Ceritinib can be increased when combined with Phenytoin. |
| Pibrentasvir | The serum concentration of Ceritinib can be increased when it is combined with Pibrentasvir. |
| Pimavanserin | The metabolism of Ceritinib can be decreased when combined with Pimavanserin. |
| Pimozide | The metabolism of Pimozide can be decreased when combined with Ceritinib. |
| Pinaverium | Pinaverium may increase the bradycardic activities of Ceritinib. |
| Pindolol | Pindolol may increase the bradycardic activities of Ceritinib. |
| Pioglitazone | The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Ceritinib. |
| Piperaquine | The metabolism of Ceritinib can be decreased when combined with Piperaquine. |
| Pirfenidone | The metabolism of Pirfenidone can be decreased when combined with Ceritinib. |
| Piroxicam | The metabolism of Piroxicam can be decreased when combined with Ceritinib. |
| Pitavastatin | The metabolism of Pitavastatin can be decreased when combined with Ceritinib. |
| Pitolisant | The serum concentration of Ceritinib can be decreased when it is combined with Pitolisant. |
| Pomalidomide | The metabolism of Pomalidomide can be decreased when combined with Ceritinib. |
| Ponatinib | The serum concentration of Ceritinib can be increased when it is combined with Ponatinib. |
| Ponesimod | The risk or severity of bradycardia can be increased when Ponesimod is combined with Ceritinib. |
| Poractant alfa | Poractant alfa may increase the bradycardic activities of Ceritinib. |
| Posaconazole | The metabolism of Ceritinib can be decreased when combined with Posaconazole. |
| Potassium Iodide | The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Ceritinib. |
| Potassium | The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Ceritinib. |
| Practolol | Practolol may increase the bradycardic activities of Ceritinib. |
| Pralsetinib | The serum concentration of Ceritinib can be increased when it is combined with Pralsetinib. |
| Pramlintide | The therapeutic efficacy of Pramlintide can be decreased when used in combination with Ceritinib. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Pramocaine. |
| Prasugrel | The metabolism of Prasugrel can be decreased when combined with Ceritinib. |
| Pravastatin | The serum concentration of Ceritinib can be increased when it is combined with Pravastatin. |
| Prednisolone | The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Ceritinib. |
| Prednisolone acetate | The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Ceritinib. |
| Prednisolone | The risk or severity of hyperglycemia can be increased when Prednisolone phosphate is combined with Ceritinib. |
| Prednisone | The risk or severity of hyperglycemia can be increased when Prednisone is combined with Ceritinib. |
| Prednisone acetate | The risk or severity of hyperglycemia can be increased when Prednisone acetate is combined with Ceritinib. |
| Pregabalin | Pregabalin may increase the bradycardic activities of Ceritinib. |
| Prenylamine | Prenylamine may increase the bradycardic activities of Ceritinib. |
| Pretomanid | The metabolism of Ceritinib can be decreased when combined with Pretomanid. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Prilocaine. |
| Primaquine | The metabolism of Ceritinib can be decreased when combined with Primaquine. |
| Primidone | The metabolism of Ceritinib can be increased when combined with Primidone. |
| Probenecid | The metabolism of Ceritinib can be increased when combined with Probenecid. |
| Probucol | The risk or severity of QTc prolongation can be increased when Probucol is combined with Ceritinib. |
| Procainamide | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Procainamide. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Procaine. |
| Prochlorperazine | The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Ceritinib. |
| Progesterone | The metabolism of Progesterone can be decreased when combined with Ceritinib. |
| Proguanil | The metabolism of Proguanil can be decreased when combined with Ceritinib. |
| Promazine | The risk or severity of QTc prolongation can be increased when Promazine is combined with Ceritinib. |
| Promethazine | The risk or severity of QTc prolongation can be increased when Promethazine is combined with Ceritinib. |
| Propafenone | Propafenone may increase the bradycardic activities of Ceritinib. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Proparacaine. |
| Propofol | The metabolism of Ceritinib can be decreased when combined with Propofol. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Propoxycaine. |
| Propranolol | Propranolol may increase the bradycardic activities of Ceritinib. |
| Propylthiouracil | The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Ceritinib. |
| Protirelin | The therapeutic efficacy of Protirelin can be decreased when used in combination with Ceritinib. |
| Protriptyline | The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Ceritinib. |
| Prucalopride | The metabolism of Prucalopride can be decreased when combined with Ceritinib. |
| Quazepam | The metabolism of Quazepam can be decreased when combined with Ceritinib. |
| Quetiapine | The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Ceritinib. |
| Quinidine | The serum concentration of Ceritinib can be increased when it is combined with Quinidine. |
| Quinine | The serum concentration of Ceritinib can be increased when it is combined with Quinine. |
| Quinupristin | The metabolism of Ceritinib can be decreased when combined with Quinupristin. |
| Raloxifene | The metabolism of Ceritinib can be decreased when combined with Raloxifene. |
| Ramelteon | The metabolism of Ramelteon can be decreased when combined with Ceritinib. |
| Ranolazine | The serum concentration of Ceritinib can be increased when it is combined with Ranolazine. |
| Regorafenib | Regorafenib may increase the bradycardic activities of Ceritinib. |
| Relugolix | The serum concentration of Ceritinib can be increased when it is combined with Relugolix. |
| Remdesivir | The metabolism of Ceritinib can be decreased when combined with Remdesivir. |
| Remifentanil | Remifentanil may increase the bradycardic activities of Ceritinib. |
| Repaglinide | The therapeutic efficacy of Repaglinide can be decreased when used in combination with Ceritinib. |
| Reserpine | The serum concentration of Ceritinib can be increased when it is combined with Reserpine. |
| Retapamulin | The metabolism of Retapamulin can be decreased when combined with Ceritinib. |
| Revefenacin | The serum concentration of Ceritinib can be increased when it is combined with Revefenacin. |
| Ribociclib | The metabolism of Ceritinib can be decreased when combined with Ribociclib. |
| Rifabutin | The metabolism of Ceritinib can be increased when combined with Rifabutin. |
| Rifampicin | The serum concentration of Ceritinib can be decreased when it is combined with Rifampicin. |
| Rifamycin | The serum concentration of Ceritinib can be increased when it is combined with Rifamycin. |
| Rifapentine | The metabolism of Ceritinib can be increased when combined with Rifapentine. |
| Rilonacept | The metabolism of Ceritinib can be increased when combined with Rilonacept. |
| Rilpivirine | The metabolism of Ceritinib can be decreased when combined with Rilpivirine. |
| Rimegepant | The serum concentration of Ceritinib can be increased when it is combined with Rimegepant. |
| Riociguat | The serum concentration of Ceritinib can be increased when it is combined with Riociguat. |
| Ripretinib | The serum concentration of Ceritinib can be increased when it is combined with Ripretinib. |
| Risperidone | The risk or severity of QTc prolongation can be increased when Risperidone is combined with Ceritinib. |
| Ritonavir | The metabolism of Ceritinib can be decreased when combined with Ritonavir. |
| Rivaroxaban | The serum concentration of Ceritinib can be increased when it is combined with Rivaroxaban. |
| Rivastigmine | Rivastigmine may increase the bradycardic activities of Ceritinib. |
| Rofecoxib | The metabolism of Ceritinib can be increased when combined with Rofecoxib. |
| Roflumilast | The serum concentration of Roflumilast can be increased when it is combined with Ceritinib. |
| Rolapitant | The serum concentration of Ceritinib can be increased when it is combined with Rolapitant. |
| Romidepsin | The metabolism of Romidepsin can be decreased when combined with Ceritinib. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Ropivacaine. |
| Rosiglitazone | The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Ceritinib. |
| Rosoxacin | The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Ceritinib. |
| Rosuvastatin | The metabolism of Ceritinib can be decreased when combined with Rosuvastatin. |
| Roxithromycin | The metabolism of Ceritinib can be decreased when combined with Roxithromycin. |
| Rucaparib | The metabolism of Ceritinib can be decreased when combined with Rucaparib. |
| Rufinamide | The metabolism of Ceritinib can be increased when combined with Rufinamide. |
| Rupatadine | The metabolism of Rupatadine can be decreased when combined with Ceritinib. |
| Ruxolitinib | Ruxolitinib may increase the bradycardic activities of Ceritinib. |
| Salbutamol | The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ceritinib. |
| Salicylic acid | The metabolism of Salicylic acid can be decreased when combined with Ceritinib. |
| Salmeterol | The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ceritinib. |
| Salmon calcitonin | The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Ceritinib. |
| Sapropterin | The serum concentration of Ceritinib can be increased when it is combined with Sapropterin. |
| Saquinavir | The metabolism of Ceritinib can be decreased when combined with Saquinavir. |
| Sarecycline | The serum concentration of Ceritinib can be increased when it is combined with Sarecycline. |
| Sarilumab | The metabolism of Ceritinib can be increased when combined with Sarilumab. |
| Satralizumab | The serum concentration of Ceritinib can be decreased when it is combined with Satralizumab. |
| Saxagliptin | The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Ceritinib. |
| Secobarbital | The metabolism of Ceritinib can be increased when combined with Secobarbital. |
| Secukinumab | The metabolism of Ceritinib can be increased when combined with Secukinumab. |
| Selegiline | The metabolism of Selegiline can be decreased when combined with Ceritinib. |
| Selexipag | The serum concentration of Ceritinib can be increased when it is combined with Selexipag. |
| Selumetinib | The metabolism of Selumetinib can be decreased when combined with Ceritinib. |
| Semaglutide | The therapeutic efficacy of Semaglutide can be decreased when used in combination with Ceritinib. |
| Sertraline | The metabolism of Sertraline can be decreased when combined with Ceritinib. |
| Sevoflurane | The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Ceritinib. |
| Sildenafil | The serum concentration of Ceritinib can be increased when it is combined with Sildenafil. |
| Silodosin | The serum concentration of Ceritinib can be increased when it is combined with Silodosin. |
| Siltuximab | The metabolism of Ceritinib can be increased when combined with Siltuximab. |
| Simeprevir | The serum concentration of Ceritinib can be increased when it is combined with Simeprevir. |
| Simvastatin | The serum concentration of Ceritinib can be increased when it is combined with Simvastatin. |
| Siponimod | The metabolism of Siponimod can be decreased when combined with Ceritinib. |
| Sirolimus | The metabolism of Sirolimus can be decreased when combined with Ceritinib. |
| Sitagliptin | The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Ceritinib. |
| Sitaxentan | The metabolism of Ceritinib can be decreased when combined with Sitaxentan. |
| Sofosbuvir | The serum concentration of Ceritinib can be increased when it is combined with Sofosbuvir. |
| Solifenacin | The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Ceritinib. |
| Somatostatin | The metabolism of Ceritinib can be decreased when combined with Somatostatin. |
| Somatrogon | The metabolism of Ceritinib can be increased when combined with Somatrogon. |
| Sonidegib | The metabolism of Sonidegib can be decreased when combined with Ceritinib. |
| Sorafenib | The serum concentration of Ceritinib can be increased when it is combined with Sorafenib. |
| Sotagliflozin | The serum concentration of Ceritinib can be increased when it is combined with Sotagliflozin. |
| Sotalol | Sotalol may increase the bradycardic activities of Ceritinib. |
| Sotorasib | The serum concentration of Ceritinib can be decreased when it is combined with Sotorasib. |
| Sparfloxacin | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Sparfloxacin. |
| St. John’s Wort | The serum concentration of Ceritinib can be decreased when it is combined with St. John’s Wort. |
| Stiripentol | The metabolism of Ceritinib can be decreased when combined with Stiripentol. |
| Sufentanil | Sufentanil may increase the bradycardic activities of Ceritinib. |
| Sulfadiazine | The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Ceritinib. |
| Sulfamethoxazole | The metabolism of Ceritinib can be decreased when combined with Sulfamethoxazole. |
| Sulfinpyrazone | The metabolism of Ceritinib can be increased when combined with Sulfinpyrazone. |
| Sulfisoxazole | The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Ceritinib. |
| Sulpiride | The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Ceritinib. |
| Sultopride | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Sultopride. |
| Sunitinib | The metabolism of Sunitinib can be decreased when combined with Ceritinib. |
| Suvorexant | The serum concentration of Ceritinib can be increased when it is combined with Suvorexant. |
| Tacrolimus | The serum concentration of Tacrolimus can be increased when it is combined with Ceritinib. |
| Talazoparib | The serum concentration of Talazoparib can be increased when it is combined with Ceritinib. |
| Tamoxifen | The serum concentration of Ceritinib can be increased when it is combined with Tamoxifen. |
| Tasimelteon | The metabolism of Ceritinib can be decreased when combined with Tasimelteon. |
| Tazemetostat | The metabolism of Ceritinib can be decreased when combined with Tazemetostat. |
| Technetium | The serum concentration of Ceritinib can be increased when it is combined with Technetium Tc-99m sestamibi. |
| Tecovirimat | The metabolism of Ceritinib can be increased when combined with Tecovirimat. |
| Tegaserod | The serum concentration of Ceritinib can be increased when it is combined with Tegaserod. |
| Telaprevir | The metabolism of Ceritinib can be decreased when combined with Telaprevir. |
| Telavancin | The risk or severity of QTc prolongation can be increased when Telavancin is combined with Ceritinib. |
| Telithromycin | The metabolism of Ceritinib can be decreased when combined with Telithromycin. |
| Telotristat ethyl | The serum concentration of Ceritinib can be decreased when it is combined with Telotristat ethyl. |
| Temsirolimus | The serum concentration of Ceritinib can be increased when it is combined with Temsirolimus. |
| Teniposide | The metabolism of Teniposide can be decreased when combined with Ceritinib. |
| Tenofovir alafenamide | The metabolism of Ceritinib can be decreased when combined with Tenofovir alafenamide. |
| Tenofovir disoproxil | The serum concentration of Ceritinib can be increased when it is combined with Tenofovir disoproxil. |
| Tenoxicam | The metabolism of Tenoxicam can be decreased when combined with Ceritinib. |
| Tepotinib | The serum concentration of Ceritinib can be increased when it is combined with Tepotinib. |
| Terbinafine | The metabolism of Ceritinib can be increased when combined with Terbinafine. |
| Terbutaline | The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ceritinib. |
| Terfenadine | The metabolism of Ceritinib can be decreased when combined with Terfenadine. |
| Teriparatide | The therapeutic efficacy of Teriparatide can be decreased when used in combination with Ceritinib. |
| Terlipressin | The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Ceritinib. |
| Testosterone | The metabolism of Ceritinib can be increased when combined with Testosterone. |
| Testosterone | The metabolism of Testosterone cypionate can be decreased when combined with Ceritinib. |
| Testosterone | The metabolism of Testosterone enanthate can be decreased when combined with Ceritinib. |
| Tetrabenazine | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Tetrabenazine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Tetracaine. |
| Tetracycline | The metabolism of Ceritinib can be decreased when combined with Tetracycline. |
| Tezacaftor | The serum concentration of Ceritinib can be increased when it is combined with Tezacaftor. |
| Thalidomide | The metabolism of Thalidomide can be decreased when combined with Ceritinib. |
| Theophylline | The metabolism of Theophylline can be decreased when combined with Ceritinib. |
| Thiamylal | The metabolism of Ceritinib can be increased when combined with Thiamylal. |
| Thioridazine | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Thioridazine. |
| Thiotepa | The metabolism of Thiotepa can be decreased when combined with Ceritinib. |
| Thiothixene | The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Ceritinib. |
| Thyroid, porcine | The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Ceritinib. |
| Thyrotropin alfa | The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Ceritinib. |
| Ticagrelor | The serum concentration of Ceritinib can be increased when it is combined with Ticagrelor. |
| Timolol | Timolol may increase the bradycardic activities of Ceritinib. |
| Tipranavir | The metabolism of Ceritinib can be decreased when combined with Tipranavir. |
| Tirzepatide | The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Ceritinib. |
| Tivozanib | The serum concentration of Ceritinib can be increased when it is combined with Tivozanib. |
| Tixocortol | The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Ceritinib. |
| Tizanidine | Tizanidine may increase the bradycardic activities of Ceritinib. |
| Tocilizumab | The metabolism of Ceritinib can be increased when combined with Tocilizumab. |
| Tofacitinib | Tofacitinib may increase the bradycardic activities of Ceritinib. |
| Tolazamide | The therapeutic efficacy of Tolazamide can be decreased when used in combination with Ceritinib. |
| Tolbutamide | The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Ceritinib. |
| Tolfenamic acid | Tolfenamic acid may increase the bradycardic activities of Ceritinib. |
| Tolterodine | The metabolism of Tolterodine can be decreased when combined with Ceritinib. |
| Tolvaptan | The metabolism of Tolvaptan can be decreased when combined with Ceritinib. |
| Topiramate | The metabolism of Ceritinib can be increased when combined with Topiramate. |
| Topotecan | The serum concentration of Topotecan can be increased when it is combined with Ceritinib. |
| Torasemide | The metabolism of Torasemide can be decreased when combined with Ceritinib. |
| Toremifene | The serum concentration of Ceritinib can be increased when it is combined with Toremifene. |
| Trabectedin | The metabolism of Trabectedin can be decreased when combined with Ceritinib. |
| Tramadol | The metabolism of Tramadol can be decreased when combined with Ceritinib. |
| Trastuzumab | The metabolism of Trastuzumab emtansine can be decreased when combined with Ceritinib. |
| Trazodone | The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ceritinib. |
| Treprostinil | The metabolism of Treprostinil can be decreased when combined with Ceritinib. |
| Tretinoin | The metabolism of Tretinoin can be decreased when combined with Ceritinib. |
| Triamcinolone | The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Ceritinib. |
| Triclabendazole | The metabolism of Ceritinib can be decreased when combined with Triclabendazole. |
| Trilaciclib | The serum concentration of Ceritinib can be increased when it is combined with Trilaciclib. |
| Trilostane | The risk or severity of hyperglycemia can be increased when Trilostane is combined with Ceritinib. |
| Trimebutine | Trimebutine may increase the bradycardic activities of Ceritinib. |
| Trimethadione | Trimethadione may increase the bradycardic activities of Ceritinib. |
| Trimethoprim | The metabolism of Trimethoprim can be decreased when combined with Ceritinib. |
| Trimipramine | The metabolism of Trimipramine can be decreased when combined with Ceritinib. |
| Triprolidine | The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Ceritinib. |
| Triptorelin | The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ceritinib. |
| Troglitazone | The metabolism of Ceritinib can be increased when combined with Troglitazone. |
| Troleandomycin | The metabolism of Ceritinib can be decreased when combined with Troleandomycin. |
| Trovafloxacin | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Trovafloxacin. |
| Tucatinib | Tucatinib may decrease the excretion rate of Ceritinib which could result in a higher serum level. |
| Ubrogepant | The serum concentration of Ubrogepant can be increased when it is combined with Ceritinib. |
| Umbralisib | The serum concentration of Ceritinib can be increased when it is combined with Umbralisib. |
| Umeclidinium | The serum concentration of Ceritinib can be increased when it is combined with Umeclidinium. |
| Valdecoxib | The metabolism of Valdecoxib can be decreased when combined with Ceritinib. |
| Valproic acid | The metabolism of Ceritinib can be decreased when combined with Valproic acid. |
| Valsartan | The metabolism of Valsartan can be decreased when combined with Ceritinib. |
| Vandetanib | The serum concentration of Ceritinib can be increased when it is combined with Vandetanib. |
| Vardenafil | The metabolism of Vardenafil can be decreased when combined with Ceritinib. |
| Velpatasvir | The serum concentration of Ceritinib can be increased when it is combined with Velpatasvir. |
| Vemurafenib | The serum concentration of Ceritinib can be increased when it is combined with Vemurafenib. |
| Venetoclax | The serum concentration of Ceritinib can be increased when it is combined with Venetoclax. |
| Verapamil | Verapamil may increase the bradycardic activities of Ceritinib. |
| Vernakalant | The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Ceritinib. |
| Vilanterol | The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Ceritinib. |
| Vildagliptin | The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Ceritinib. |
| Viloxazine | The metabolism of Ceritinib can be decreased when combined with Viloxazine. |
| Vinblastine | The metabolism of Ceritinib can be increased when combined with Vinblastine. |
| Vincristine | The metabolism of Vincristine can be decreased when combined with Ceritinib. |
| Vindesine | The metabolism of Vindesine can be decreased when combined with Ceritinib. |
| Vinflunine | The metabolism of Vinflunine can be decreased when combined with Ceritinib. |
| Vinorelbine | The metabolism of Vinorelbine can be decreased when combined with Ceritinib. |
| Vismodegib | The metabolism of Vismodegib can be decreased when combined with Ceritinib. |
| Vitamin E | The metabolism of Ceritinib can be increased when combined with Vitamin E. |
Pregnancy and Lactation
FDA Pregnancy Category D
Pregnancy
Based on animal studies and its mechanism of action, ceritinib therapy can cause fetal harm when administered to a pregnant woman. The limited data available on the use of ceritinib in pregnant women are insufficient to inform risk. Administration to rats and rabbits during the period of organogenesis at maternal plasma exposures below the recommended human dose caused increases in skeletal anomalies in rats and rabbits. Pregnant women should be advised of the potential risk to the fetus. Females of reproductive potential are advised to use effective contraception during treatment with ceritinib and for 6 months following the completion of therapy. Based on the potential for genotoxicity, males with female partners of reproductive potential are advised to use condoms during treatment with ceritinib and for 3 months following completion of therapy.
Lactation
No information is available on the clinical use of ceritinib during breastfeeding. Because ceritinib is 97% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during ceritinib therapy and for 2 weeks after the final dose. There are no data regarding the presence of ceritinib or its metabolites in human milk, the effects of ceritinib on breastfed infants, or its effects on milk production. Because of the potential for serious adverse reactions including gastrointestinal toxicity, hepatotoxicity, pneumonitis, bradycardia, and pancreatitis, breastfeeding is not recommended during treatment with ceritinib and for 2 weeks following completion of therapy.
How should this medicine be used?
Ceritinib comes as a capsule and a tablet to take by mouth. It is usually taken with food once a day. Take ceritinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take ceritinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
If you vomit after taking ceritinib, do not take another dose. Continue your regular dosing schedule.
Your doctor may decrease your dose of ceritinib, treat you with other medications, or tell you to stop taking ceritinib for a period of time during your treatment. This will depend on how well the medication works for you and any side effects you may experience. Be sure to tell your doctor how you are feeling during your treatment with ceritinib.
What special precautions should I follow?
Before taking ceritinib,
- tell your doctor and pharmacist if you are allergic to ceritinib, any other medications, or any of the ingredients in ceritinib capsules or tablets. Ask your pharmacist for a list of the ingredients.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: amiodarone (Nexterone, Pacerone); anagrelide (Agrylin); anticoagulants (‘blood thinners’) such as warfarin (Coumadin, Jantoven); beta blockers such as atenolol (Tenormin), labetalol (Normodyne), metoprolol (Lopressor, Toprol XL), nadolol (Corgard), propranolol (Inderal) and sotalol (Betapace, Sorine, Sotylize); carbamazepine (Carbatrol, Epitol, Equetro, Tegretol, Teril); certain medications for human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) such as efavirenz (Sustiva, in Atripla), indinavir (Crixivan), nelfinavir (Viracept), nevirapine (Viramune), ritonavir (Norvir, in Kaletra), and saquinavir (Invirase); chloroquine; chlorpromazine; cilostazol; ciprofloxacin (Cipro); citalopram (Celexa); clarithromycin; clonidine (Catapres, Kapvay); corticosteroids; cyclosporine (Gengraf, Neoral, Sandimmune); digoxin (Lanoxin); diltiazem (Cardizem, Dilacor, Tiazac); disopyramide (Norpace); dofetilide (Tikosyn); donepezil (Aricept); dronedarone (Multaq); escitalopram (Lexapro); fentanyl (Abstral, Actiq, Duragesic, Fentora, Subsys); flecainide (Tambocor); fluconazole (Diflucan); haloperidol (Haldol); ibutilide (Corvert); itraconazole (Onmel, Sporanox, Tolsura); ketoconazole; levofloxacin; methadone (Dolophine, Methadose); moxifloxacin (Avelox); nefazodone; ondansetron (Zuplenz, Zofran); pentamidine (Pentam); phenobarbital; phenytoin (Dilantin, Phenytek); pimozide (Orap); pioglitazone (Actos, in Duetact, Oseni); procainamide; quinidine (in Nuedexta); rifabutin (Mycobutin); rifampin (Rifadin, Rimactane, in Rifater); sildenafil (Revatio); sirolimus (Rapamune); tacrolimus (Astagraf, Prograf); thioridazine; vardenafil (Levitra, Staxyn); and verapamil (Calan, Covera, Isoptin, Verelan). Many other medications may interact with ceritinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
- tell your doctor what herbal products you are taking, especially St. John’s Wort.
- tell your doctor if you have or have ever had diabetes or high blood sugar, heart failure, an irregular heartbeat, QT prolongation (an irregular heart rhythm that can lead to fainting, loss of consciousness, seizures, or sudden death), a low level of potassium or magnesium in your blood, pancreatitis (inflammation of the pancreas), or liverdisease.
- tell your doctor if you are pregnant, or plan to become pregnant. You should not become pregnant while you are taking ceritinib. You will need to have a pregnancy test before you start treatment, and you should use birth control to prevent pregnancy during your treatment and for at least 6 months after your final dose. If you are a male with a female partner who may become pregnant, you should use birth control to prevent pregnancy during you treatment and for at least 3 months after your final dose. Talk to your doctor about birth control methods that will work for you. Ceritinib may harm your unborn baby. If you or your partner become pregnant during your treatment with ceritinib, call your doctor immediately.
- tell your doctor if you are breastfeeding. You should not breastfeed while you are taking ceritinib and for at least 2 weeks after your final dose.
- if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking ceritinib.
- you should know that you may experience hyperglycemia (an increase in your blood sugar) while you are taking this medication. Tell your doctor immediately if you have any of the following symptoms while you are taking ceritinib: extreme thirst, frequent urination, extreme hunger, blurred vision, headache, trouble thinking or concentrating, breath that smells like fruit or tiredness.
References
